The Bill & Melinda Gates Foundation and GlaxoSmithKline have begun a $1.8 million partnership to develop adjuvants that help malaria and HIV drugs better withstand heat. The project's first goal will be the development of adjuvant AS01, which is used in the company's RTS,S malaria vaccine candidate and other vaccines for HIV and tuberculosis. The collaboration is part of the Gates Foundation's Vaccine Discovery Partnership.

Related Summaries